**Mesna**

**Essential medicine status**

**Section:** 8. Immunomodulators and antineoplastics  ➤  8.2. Antineoplastics and supportive medicines  ➤  8.2.5. Supportive medicines

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for mesna on the complementary list of the EML and EMLc for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.

---

**Indication**

- Rhabdomyosarcoma primary site

**INN**

- Mesna

**Medicine type**

- Chemical agent

**List type**

- Complementary (EML) (EMLc)

**Formulations**

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg

**EML status history**

- First added in 2015 (TRS 994)

**Sex**

- All

**Age**

- Also recommended for children

**Therapeutic alternatives**

- The recommendation is for this specific medicine

**Patent information**

- Patents have expired in most jurisdictions

**Tags**

- Cancer

**Wikipedia**

- Mesna

**DrugBank**

- Mesna (Coenzyme M)